MedTrace Logo

of Androgen Receptor Expression in Breast Cancer With or Without BRCA Mutation

NCT05404334 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 231

Last updated 2024-08-13

No results posted yet for this study

Summary

Androgen Receptor is extensively expressed in BRCA and its role in the disease may differ depending upon molecular subtypes and stages. Androgen Receptor (AR) may act as an antagonist of estrogen receptor α (ERα), in ERα induced effect, whereas in the absence of estrogens, AR may act as an agonist, of ERα- promoting tumor. Thus, depending on the BRCA micro-environment, both agonists and antagonists of the AR have been suggested for therapeutic approaches.

Conditions

Interventions

DIAGNOSTIC_TEST

Androgen receptor status and BRCA mutation

Androgen receptor status by IHC and germ line BRCA mutation

Sponsors & Collaborators

  • Banaras Hindu University

    lead OTHER

Principal Investigators

  • Manoj Pandey, MS, PhD · Banaras Hindu University

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2024-07-01
Completion
2024-07-01

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05404334 on ClinicalTrials.gov